Drug Profile
Research programme: staphylococcus aureus vaccine - Astellas Pharma/Boston Children's Hospital/ClearPath Development Company
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Astellas Pharma; ClearPath Development Company
- Developer Astellas Pharma; Boston Childrens Hospital; ClearPath Development Company
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Staphylococcal-infections(Prevention) in USA
- 19 Dec 2017 ClearPath Development Company, under strategic partnership with Astellas Pharma, agrees to co-develop Staphylococcus aureus vaccine with Boston Children's Hospital
- 19 Dec 2017 Early research in Staphylococcal infections (Prevention) in USA (unspecified route)